Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?

Michelle Meyer, Delphine C. Malherbe, Alexander Bukreyev

    Research output: Contribution to journalArticle

    3 Citations (Scopus)

    Abstract

    Testing vaccine efficacy against the highly lethal Ebola virus (EBOV) in humans is almost impossible due to obvious ethical reasons and the sporadic nature of outbreaks. For such situations, the ‘animal rule’ was established, requiring the product be tested in animal models, expected to predict the response observed in humans. For vaccines, this testing aims to identify immune correlates of protection, such as antibody or cell-mediated responses. In the wake of the 2013–2016 EBOV epidemic, and despite advancement of promising candidates into clinical trials, protective correlates remain ambiguous. In the hope of identifying a reliable correlate by comparing preclinical and clinical trial data on immune responses to vaccination, we conclude that correlates are not universal for all EBOV vaccines.

    Original languageEnglish (US)
    JournalTrends in Microbiology
    DOIs
    StateAccepted/In press - Jan 1 2018

    Fingerprint

    Ebola Vaccines
    Ebolavirus
    Vaccines
    Clinical Trials
    Disease Outbreaks
    Vaccination
    Animal Models
    Antibodies

    Keywords

    • Ebola
    • immune correlates
    • immunity
    • protection
    • vaccine

    ASJC Scopus subject areas

    • Microbiology
    • Microbiology (medical)
    • Infectious Diseases
    • Virology

    Cite this

    Can Ebola Virus Vaccines Have Universal Immune Correlates of protection? / Meyer, Michelle; Malherbe, Delphine C.; Bukreyev, Alexander.

    In: Trends in Microbiology, 01.01.2018.

    Research output: Contribution to journalArticle

    @article{bbd5a28c2f8945c9a544b12a52ae2d75,
    title = "Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?",
    abstract = "Testing vaccine efficacy against the highly lethal Ebola virus (EBOV) in humans is almost impossible due to obvious ethical reasons and the sporadic nature of outbreaks. For such situations, the ‘animal rule’ was established, requiring the product be tested in animal models, expected to predict the response observed in humans. For vaccines, this testing aims to identify immune correlates of protection, such as antibody or cell-mediated responses. In the wake of the 2013–2016 EBOV epidemic, and despite advancement of promising candidates into clinical trials, protective correlates remain ambiguous. In the hope of identifying a reliable correlate by comparing preclinical and clinical trial data on immune responses to vaccination, we conclude that correlates are not universal for all EBOV vaccines.",
    keywords = "Ebola, immune correlates, immunity, protection, vaccine",
    author = "Michelle Meyer and Malherbe, {Delphine C.} and Alexander Bukreyev",
    year = "2018",
    month = "1",
    day = "1",
    doi = "10.1016/j.tim.2018.08.008",
    language = "English (US)",
    journal = "Trends in Microbiology",
    issn = "0966-842X",
    publisher = "Elsevier Limited",

    }

    TY - JOUR

    T1 - Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?

    AU - Meyer, Michelle

    AU - Malherbe, Delphine C.

    AU - Bukreyev, Alexander

    PY - 2018/1/1

    Y1 - 2018/1/1

    N2 - Testing vaccine efficacy against the highly lethal Ebola virus (EBOV) in humans is almost impossible due to obvious ethical reasons and the sporadic nature of outbreaks. For such situations, the ‘animal rule’ was established, requiring the product be tested in animal models, expected to predict the response observed in humans. For vaccines, this testing aims to identify immune correlates of protection, such as antibody or cell-mediated responses. In the wake of the 2013–2016 EBOV epidemic, and despite advancement of promising candidates into clinical trials, protective correlates remain ambiguous. In the hope of identifying a reliable correlate by comparing preclinical and clinical trial data on immune responses to vaccination, we conclude that correlates are not universal for all EBOV vaccines.

    AB - Testing vaccine efficacy against the highly lethal Ebola virus (EBOV) in humans is almost impossible due to obvious ethical reasons and the sporadic nature of outbreaks. For such situations, the ‘animal rule’ was established, requiring the product be tested in animal models, expected to predict the response observed in humans. For vaccines, this testing aims to identify immune correlates of protection, such as antibody or cell-mediated responses. In the wake of the 2013–2016 EBOV epidemic, and despite advancement of promising candidates into clinical trials, protective correlates remain ambiguous. In the hope of identifying a reliable correlate by comparing preclinical and clinical trial data on immune responses to vaccination, we conclude that correlates are not universal for all EBOV vaccines.

    KW - Ebola

    KW - immune correlates

    KW - immunity

    KW - protection

    KW - vaccine

    UR - http://www.scopus.com/inward/record.url?scp=85052922298&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85052922298&partnerID=8YFLogxK

    U2 - 10.1016/j.tim.2018.08.008

    DO - 10.1016/j.tim.2018.08.008

    M3 - Article

    JO - Trends in Microbiology

    JF - Trends in Microbiology

    SN - 0966-842X

    ER -